93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)BPDCN…
Exploring the infinite frontiers of an intelligent connected world WUXI, China, Nov. 3, 2025 /PRNewswire/ -- The World Internet of…